Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that updated interim results from its ongoing Phase 1 ACESOT-1051 study of WEE1 inhibitor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE